Detail Information of Xenobiotics
| General Information of Xenobiotics (ID: XEO00678) | ||||||
|---|---|---|---|---|---|---|
| Xenobiotics Name |
Dinaciclib
|
|||||
| Xenobiotics Type |
Pharmaceutical Agent(s)
|
|||||
| Classification |
Drug in Phase 3 Clinical Trial
|
|||||
| Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=46926350"></iframe>
|
 |
||||
| 3D MOL | 2D MOL | |||||
| PubChem CID | ||||||
| DME(s) Modulated by This Xenobiotics | ||||||
| DME(s) Inhibited by This Xenobiotics | ||||||
| Aldo-keto reductase 1C3 (AKR1C3) | DME Info | Homo sapiens | [1] | |||
| References | ||||||
| 1 | Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile. Arch Toxicol. 2018 Sep;92(9):2845-2857. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.